Metabolic and electrocardiographic effects of albuterol in pediatric asthmatic patients treated in an emergency room setting

Allergologia et Immunopathologia

Volumn 27, Issue 1, 1999, Pages 18-23

  Del Rio Navarro B ^b   Gazca Aguilar, A ^b   Quibrera Matienzo, J A ^b   Rodriguez Galvan Y ^b   Sienra Monge, Juan José L ^a  

^a HOSPITAL INFANTIL DE MÉXICO FEDERICO GÓMEZ   (Mexico)

^b NONE

Author keywords

Albuterol; Asthma; Cardiovascular effects

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; POTASSIUM; SALBUTAMOL;

ARTERIAL OXYGEN SATURATION; ASTHMA; BRONCHODILATATION; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DRUG SAFETY; HEART ELECTROPHYSIOLOGY; HUMAN; POTASSIUM BLOOD LEVEL; POTASSIUM METABOLISM; QT INTERVAL; TREMOR;

ALBUTEROL; BLOOD GAS ANALYSIS; BRONCHODILATOR AGENTS; CHILD; ELECTROCARDIOGRAPHY; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEART; HEART RATE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; POTASSIUM; STATUS ASTHMATICUS;

EID: 0032905062     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Mitchel EA. International trends in hospital admission rates for asthma. Arch Dis Child 1985;10:376-8.
2. Meza C, Gershwin ME. Why is asthma becoming more of a problem? Curr Opin Pulm Med 1997;3:6-9.
3. Colin SW, Pavord DI. Bronchodilator, cardiovascular and hypokalemic effects of fenoteral, salbutamol and terbutaline in asthma. Lancet 1990;336:1396-9.
4. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death rate from asthma in New Zealand, 1981-83: case-control study. Lancer 1989;i:917-22.
5. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-1981. Thorax 1990;45:170-5.
6. Suissa S, Hemmelgarn B, Biais L, Ernst P. Bronchodilators and acute cardiac death. Am J Resp Crit Care Med 1996;154:1598-1602.
7. Kurland GW, Lewinston NJ. Fatal myocardial toxicity during continuous infusion intravenous isoproterenol therapy of asthma. J Allergy Clin Immunol 1979;63:407.
8. Maguire JF, Geha Rs, Umetsu DT. Myocardial specific creatinine phosphokinase isoenzyme elevation associated with intravenous usoproterenol therapy of childhood asthma. J Allergy Clin Immunol 1986;78:631-6.
9. Matson J, Loughin G, Strunk R. Myocardial ischemia complication the use of isoproterenol is asthmatic children. J Pediatric 1978;92:776.
10. Aelony Y, Lakes MM, Beall G. An electrocardiographic pattern of acute myocardial infarction associated with excessive use of aerosolized isoproterenol. Chest 1975;68:107.
11. Newhouse MT, Chapman KR, McCallum AL, Abboud TR, Bowie DM, Hodder RV, Pare PD, Mesi-Fuchs H, Molfino NA. Cardiovascular safety of high doses of inhaled fenoterol and albuterol in acute sever asthma. Chest 1996;110:595-603.
12. Maconochie JG, Minton NA, Chilton JE, Keene ON. Does tachyphylaxis occur to the non-pulmonary effects of salmeterol? Br J Clin Pharmacol 1994;37:199-204.
13. Rodrigo G, Rodrigo C. Metered dose inhaler salbutamol treatment of asthma in the DE: comparison of two doses with plasma levels. Am J Emerg Med 1996;14:144-50.
14. Bentur L, Canny GJ, Shields MD, Kerem E, Schuh S, Reisman JJ, Fakhoury K, Pedder L, Levison H. Controlled trial of nebulized albuterol in children younger than 2 years of age with acute asthma. Pediatrics 1992;89:133-7.
15. Bierman CW, Kemp JP, Nathan RA. Efficacy and safety of inhaled bitolterol mesylate via metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol 1996;76:27-35.
16. Katz RW, Kelly W, Crowlwy MR, Grad R, McWilliams BC, Murphy SF. Safety of continuous nebulized albuterol for bronchospasm in infants and children. Pediatrics 1993; 92:666-9.
17. Craig VL, Bigos D, Brilli RJ. Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Pediatr Emerg Care 1996;12:1-5.
18. Montgomery VL, Eid NS. Low-dose beta agonist continuous nebulization therapy for status asthmaticus in children. J Asthma 1994;31:201-7.
19. Papo MC, FranK J, Thompson AE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med 1993;21:1479-86.
20. Wood DW, Downes JJ, Leeks HI. A clinical scoring system for the diagnosis of respiratory failure. Preliminary report on childhood status asthmaticus. Amer J Dis Child 1972;123:227-8.
21. Bazett HC. An analysis of the time-relation of the electrocardiogram. Heart 1920;7:353-70.
22. Campbell MJ, Cogman GR, Holgate ST, Johnston SL. Age specific trends in asthma mortality in England and Wales, 1983-95: results of an observational study. BMJ 1997;1439-41.
23. Sly RM, O'Donnell R. Stabilization of asthma mortality. Ann Allergy Asthma Immunol 1997;78:347-54.
24. Mormile F, Chiappini F, Feola G, Ciappi G. Deaths from asthma in Italy (1974-1988): is there a relationship with changing pharmacological approaches? J Clin Epidemiol 1996;49:1459-66.
25. Shrestha M, Bidadi K, Gourlay S, Hayes J. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Chest 1996;110:42-7.
26. Bremner P, Siebers R, Crane J, Beasley R, Burgess C. Partial vs full beta-receptor agonism a clinical study of inhalaed albuterol and fenoterol. Chest 1996;109:957-62.
27. McFadden ER, Warren EL. Observations on asthma mortality. Ann Intern Med 1997;127:142-7.
28. a ed. Barcelona: Salvat: 1946. p. 1328-9.